Bio X Cell

Your trusted supplier of in vivo MAbs

For more than 25 years, scientists have trusted Bio X Cell as their go-to source for in vivo functional grade antibodies. Bio X Cell take this responsibility to heart and have always focused their efforts on one goal: producing the highest-quality antibodies with the best value possible. By doing this, they help scientists research with confidence and discover faster.

Bio X Cell unwavering commitment to scientists has inspired them to create and optimize a proprietary in vivo antibody manufacturing method with significant advantages that directly benefit their customers.

Their industry-leading InVivoMAb™ and InVivoPlus™ antibodies are all manufactured in their own facility in the US and never outsourced from another manufacturer, giving them full control over the quality and availability of their products.

“I am totally satisfied with the service Bio X Cell has given us. When anyone asks me for CTLA-4 antibodies, I always refer them to you. I look forward to another 20 years.”

– James P. Allison (2018 Nobel Prize Corecipient in Physiology or Medicine)

Bio-Connect Life Sciences supplies all their products in the Benelux. If you have any questions, please contact the helpdesk.

Major product lines from Bio X Cell

  • Monoclonal antibodies
  • Biosimilar antibodies
  • Recombinant monoclonal antibodies
  • Fusion proteins
  • Isotype controls
  • Contract production/purification from hybridomas

Top sellers

InVivoMab anti-mouse PD-1 (CD279) (BE0146)
InVivoMab rat IgG2a isotype control (BE0089)
InVivoMab anti-mouse PD-1 (CD279) (BP0146)
InVivoMab anti-mouse PD-L1 (B7-H1) (BE0101)
InVivoMab rat IgG2b isotype control (BE0090)
InVivoMab rat IgG2a isotype control (BP0089)
InVivoMab mouse IgG1 isotype control (BE0083)
InVivoMab anti-mouse CD4 (BE0003-1)
InVivoMab anti-mouse PD-1 (CD279) (BE0273)
InVivoMab anti-mouse PD-L1 (B7-H1) (BP0101)
More products can be found in our webshop

Contract antibody production service

At Bio X Cell, they know that growing hybridoma cells and purifying antibodies in the quantities needed for in vivo pre-clinical research can be technically challenging and time-consuming. For over 20 years, their industry-leading antibodies and antibody production services have allowed their customers more time to focus on accelerating research discoveries. Their platform focuses on antibody production from pre-existing hybridoma cell lines, and is easily scalable to deliver the large quantities required for in vivo research. Read more »»

Publications with products by Bio X Cell

  • Grasselly C, et al. The antitumor activity of combinations of cytotoxic chemotherapy and immune checkpoint inhibitors is model-dependent. Front Immunol. 2018;9:2100.
  • Stathopoulou C, et al. Pd-1 inhibitory receptor downregulates asparaginyl endopeptidase and maintains foxp3 transcription factor stability in induced regulatory t cells. Immunity. 2018;49(2):247-263.e7.
  • Balogh KN, et al. Macrophage Migration Inhibitory Factor protects cancer cells from immunogenic cell death and impairs anti-tumor immune responses. PLoS One. 2018;13(6):e0197702.
  • Wang W, et al. Rip1 kinase drives macrophage-mediated adaptive immune tolerance in pancreatic cancer. Cancer Cell. 2018;34(5):757-774.e7.
  • Ariyan CE, et al. Robust antitumor responses result from local chemotherapy and ctla-4 blockade. Cancer Immunol Res. 2018;6(2):189-200.
  • Dai M, et al. Curing mice with large tumors by locally delivering combinations of immunomodulatory antibodies. Clin Cancer Res. 2015;21(5):1127-1138.
  • Davis RW, et al. Luminol chemiluminescence reports photodynamic therapy-generated neutrophil activity in vivo and serves as a biomarker of therapeutic efficacy. Photochem Photobiol. 2019;95(1):430-438.
  • Burrack KS, et al. Interleukin-15 complex treatment protects mice from cerebral malaria by inducing interleukin-10-producing natural killer cells. Immunity. 2018;48(4):760-772.e4.
  • Wynn JL, et al. Neonatal cd71+ erythroid cells do not modify murine sepsis mortality. J Immunol. 2015;195(3):1064-1070.
  • Li J, et al. Co-inhibitory molecule b7 superfamily member 1 expressed by tumor-infiltrating myeloid cells induces dysfunction of anti-tumor cd8+ t cells. Immunity. 2018;48(4):773-786.e5.

Related products

Related news

Newsletter for researchers

We gladly support you by keeping you updated on our latest products and the developments around our services.

we Connect you
Need help? Contact our technical support